Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/01/2023 |
PubMed |
Ac-SDKP promotes KIF3A-mediated Ī²-catenin suppression through a ciliary mechanism to constrain silica-induced epithelial-myofibroblast transition. |
|
04/20/2023 |
PubMed |
[Meta-analysis of Ac-SDKP inhibition of Pulmonary fibrosis in animal models]. |
|
02/20/2023 |
PubMed |
[Review on biological effects and mechanism of Ac-SDKP]. |